NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2020 Financial Results Conference Call
22 janv. 2021 11h05 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2020 fourth quarter and full year financial results before the opening of...
NeuroMetrix Reports Q3 2020 Financial Results
22 oct. 2020 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2020. The Company is a leading...
NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call
15 oct. 2020 11h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on...
NeuroMetrix Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-the-Counter Pain Relief Device
22 sept. 2020 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the launch of the Quell Watch App, now available for download from the Apple App store. Quell is a...
NeuroMetrix Announces Issuance of New U.S. Patent for Quell® Wearable Technology
21 sept. 2020 13h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office will issue on September 22, 2020 U.S. Patent No....
NeuroMetrix Reports Scientific Presentation at the PAINWeek 2020 Live Virtual Conference
04 sept. 2020 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it will present a scientific poster at the PAINWeek 2020 Live Virtual Conference to be...
NeuroMetrix Reports Publication of Study Validating DPNCheck® Staging of Diabetic Peripheral Neuropathy Severity
01 sept. 2020 13h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the publication of a large study demonstrating that DPNCheck effectively determines the severity of...
NeuroMetrix Reports that Quell® is to be Evaluated for Chemotherapy-Induced Peripheral Neuropathy in NIH-Funded Clinical Trial
20 août 2020 14h11 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell device will be used in an NIH-funded, multi-site randomized controlled trial (RCT) of...
Quell® Fills Unmet Need for Chronic Knee Pain Relief that is Drug-Free
10 août 2020 10h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) published an infographic on chronic knee pain (available here) and provided an update on how Quell technology...
NeuroMetrix Reports Q2 2020 Financial Results
23 juil. 2020 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading...